⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRSNW News
NeuroSense Therapeutics Ltd. Warrant
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
prnewswire.com
NRSNW
NRSN
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
prnewswire.com
NRSNW
NRSN
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
prnewswire.com
NRSNW
NRSN